SGLT2 Inhibitors Linked to Lower Hyperkalemia Risk and Improved RAASi Continuation suggests new study Dr. Shravani Dali8 May 2025 8:45 AM ISTSGLT2 Inhibitors Linked to Lower Hyperkalemia Risk and Improved RAASi Continuation suggests a new study published in the JAMA .Hyperkalemia is a...
Addition of Metformin to SGLT2 Inhibitors Lowers Kidney Disease Risk in Diabetes Patients: Study Dr Riya Dave14 March 2025 9:00 AM ISTResearchers have found in a new study that patients receiving a combination of metformin and SGLT2 inhibitors experienced a significant reduction in...
Updated chronic kidney disease management guidelines recommend SGLT2 inhibitors regardless of diabetes or kidney disease type Dr. Kamal Kant Kohli12 March 2025 7:00 AM ISTThe Kidney Disease: Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 on evaluation and...
SGLT2 Inhibitors May Lower Risk of Atopic Dermatitis in Diabetics: Study Dr Riya Dave10 March 2025 10:45 PM ISTResearchers have identified in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT2i) could diminish the risk for the development of...
SGLT2 Inhibitors exhibit Potential for Slowing Aortic Stenosis Progression: Study Dr. Shravani Dali21 Feb 2025 8:15 AM ISTResearchers have found in a new study that SGLT2 inhibitors may have disease-modifying effects in nonsevere aortic stenosis (AS). After adjustments,...
SGLT2 inhibitors may reduce atherothrombotic major CV events in diabetes patients: Study Jacinthlyn Sylvia14 Jan 2025 9:30 AM ISTA recent study conducted across public hospitals in Hong Kong highlighted the superiority of sodium-glucose cotransporter 2 (SGLT2) inhibitors over...
Research Highlights Expanded Clinical Uses of SGLT2 Inhibitors Medha Baranwal6 Jan 2025 8:30 AM ISTUSA: A recent editorial published in the Journal of Cardiothoracic and Vascular Anesthesia highlights the growing clinical applications of...
Diabetes Drugs SGLT2i and GLP-1 RAs may Reduce Risk of Pneumonia and Sepsis, finds research Dr Riya Dave19 Dec 2024 8:15 AM ISTResearchers have discovered that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), often...
Canagliflozin Enhances Iron Utilization and Hemoglobin Levels in Diabetic CKD Patients, CREDENCE Trial Reveals Dr Kartikeya Kohli13 Nov 2024 9:30 AM ISTAustralia: Recent findings from the CREDENCE trial have shed light on the significant role of Canagliflozin, a sodium-glucose co-transporter 2 (SGLT2)...
Study Reveals Significant Care Gap in SGLT2 Inhibitor Use for Diabetes and HF, Despite Real-World Benefits Medha Baranwal11 Sept 2024 9:45 AM ISTRecent study highlights a significant care gap due to the underuse of SGLT2 inhibitors, despite their benefits.Canada: A recent population-level...
SGLT2 inhibitors promising in improving kidney outcomes for older patients with diabetic kidney disease: Real-World Study Dr Kartikeya Kohli24 July 2024 8:00 PM ISTJapan: In the ongoing battle against diabetic kidney disease (DKD), a recent real-world study conducted in Japan has shed new light on the potential...
Empagliflozin Use Leads to Rare Case of Emphysematous Cystitis in Non-Diabetic Patient: Case Study Medha Baranwal8 July 2024 8:30 AM ISTMalta: A recent case study published in Cureus Journal has described a rare medical case in which the use of empagliflozin, a medication typically...
